As I've lamented before, there just aren't many ways for investors to play the ophthalmology market. Aside from a few small biotech/pharma companies and Cooper (NYSE:COO), the bulk of the industry is locked away within larger companies like Allergan (NYSE:AGN) and Novartis (NYSE:NVS). But it's not just scarcity value that makes TearLab (NASDAQ:TEAR) interesting. TearLab has developed a quick test for dry eye disease that not only can be done in the doctor's office, but is actually profitable for the doctor to do. With an innovative test and a tried-and-true disposables-based model with a low breakeven level, TearLab could be an interesting small-cap speculation even here after a doubling in the stock....
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|